Constitutive IL-8 expression in cancer cells is associated with mutation of p53

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 1, 2005, Pages 127-133

  Hidaka, Hideki ^a   Ishiko, T ^b   Ishikawa, S ^b   Ikeda, O ^b   Mita, S ^b   Iwamura, T ^a   Chijiiwa, K ^a   Ogawa, M ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer cell; IL 8; NF B; P53

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PROTEIN P53;

ARTICLE; CANCER; CANCER CELL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE TRANSFER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-8; MUTATION; NEOPLASMS; NF-KAPPA B; TUMOR SUPPRESSOR PROTEIN P53;

EID: 18544381209     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Belperio J.A., Keane M.P., Arenberg D.A. et al.: CXC chemokines in angiogenesis. J. Leukoc. Biol. 68: 1-8, 2000.
2. Strieter R.M., Polverini P.J., Kunkel S.L. et al.: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270: 27348-27357, 1995.
3. Kim S.J., Uehara H., Karashima T., McCarty M., Shih N., Fidler I.J.: Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 3: 33-42, 2001.
4. Shi Q., Abbruzzese J.L., Huang S., Fidler I.J., Xiong Q., Xie K.: Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin. Cancer Res. 5: 3711-3721, 1999.
5. Ishiko T., Sakamoto K., Yamashita S. et al.: Carcinoma cells express 1L-8 and the 1L-8 receptor: Their inhibition attenuates the growth of carcinoma cell. Int. J. Oncol. 6: 119-122, 1995.
6. Takamori H., Oades Z.G., Hoch O.C., Burger M., Schraufstatter I.U.: Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas 21: 52-56, 2000.
7. Xu L., Fidler I.J.: Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol. Res. 12: 97-106, 2000.
8. Kunsch C., Lang R.K., Rosen C.A., Shannon M.F.: Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6. J. Immunol. 153: 153-164, 1994.
9. Ott M., Lovett J.L., Mueller L., Verdin E.: Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. J. Immunol. 160: 2872-2880, 1998.
10. Beg A.A., Baltimore D.: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784, 1996.
11. Wang C.Y., Mayo M.W., Baldwin A.S., Jr.: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996.
12. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S., Jr.: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
13. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M.: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787-789, 1996.
14. Wu M.X., Ao Z., Prasad K.V., Wu R., Schlossman S.F.: IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science 281: 998-1001, 1998.
15. Stehlik C., de Martin R., Kumabashiri I., Schmid J.A., Binder B.R., Lipp J.: Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med. 188: 211-216, 1998.
16. Giri D.K., Aggarwal B.B.: Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J. Biol. Chem. 273: 14008-14014, 1998.
17. Bellas R.E., FitzGerald M.J., Fausto N., Sonenshein G.E.: Inhibition of NF-kappa B activity induces apoptosis in murine hepatocytes. Am. J. Pathol. 151: 891-896, 1997.
18. Gudas J., Nguyen H., Li T., Hill D., Cowan K.H.: Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Wafl expression in human breast epithelial cells. Oncogene 11: 253-261, 1995.
19. Kuerbitz SJ., Plunkett B.S., Walsh W.V., Kastan M.B.: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. U S A 89: 7491-7495, 1992.
20. Yeargin J., Haas M.: Elevated levels of wild-type p53 induced by radiolabeling of cells leads to apoptosis or sustained growth arrest. Curr. Biol. 5: 423-431, 1995.
21. Harris C.C.: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88: 1442-1455, 1996.
22. Fujiwara T., Cai D.W., Georges R.N., Mukhopadhyay T., Grimm E.A., Roth J.A.: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86: 1458-1462, 1994.
23. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A.: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54: 2287-2291, 1994.
24. Ogawa N., Fujiwara T., Kagawa S. et al.: Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int. J. Cancer 73: 367-370, 1997.
25. Iwamura T., Katsuki T., Ide K.: Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn. J. Cancer Res. 78: 54-62, 1987.
26. Fiedler M.A., Wemke-Dollries K., Stark J.M.: Inhibition of TNF-alpha-induced NF-kappaB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132. Am. J. Respir. Cell. Mol. Biol. 19: 259-268, 1998.
27. Thompson C.D., Frazier-Jessen M.R., Rawat R., Nordan R.P., Brown R.T.: Evaluation of methods for transient transfection of a murine macrophage cell line, RAW 264.7. Biotechniques 27: 824-826, 28-30, 32, 1999.
28. Fronsdal K., Engedal N., Slagsvold T., Saatcioglu F.: CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J. Biol. Chem. 273: 31853-31859, 1998.
29. Sheppard K.A., Phelps K.M., Williams A.J. et al: Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biol. Chem. 273: 29291-29294, 1998.
30. Webster G.A., Perkins N.D.: Transcriptional cross talk between NF-kappaB and p53. Mol. Cell Biol. 19: 3485-3495, 1999.
31. Ravi R., Mookerjee B., van Hensbergen Y. et al.: p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional i ntegrator p300. Cancer Res. 58: 4531-4536, 1998.